AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Veru Inc.
Video analysis: VERU
All videosNo video analysis for this stock yet. Request one from our team.
News: VERU
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant metastatic prostate cancer—
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D.
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Canaccord Genuity's 46th Annual Growth Conference, in Boston, Massachusetts, on August 12, 2026 at 2:00 pm – 2:25 pm Eastern Daylight Time.
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the completion of enrollment in the Phase 2b PLATEAU clinical study to evaluate the effect of oral enobosarm 3 mg versus placebo on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in ~200 older patients (age ≥ 65 years) who have obesity (BMI ≥ 35) and are initiating semaglutide treatment for weight reduction. The interim analysis results from the study are expected in the first quarter of calendar year 2027 with final topline clinical data expected in the fourth quarter of calendar year 2027.
Similar companies
-
BioXcel Therapeutics, Inc.
BTAI
·
NASDAQ
Compare
-
Annovis Bio, Inc.
ANVS
·
New York Stock Exchange
Compare
-
Celularity Inc.
CELU
·
NASDAQ
Compare
-
PolyPid Ltd.
PYPD
·
NASDAQ
Compare
-
Reviva Pharmaceuticals Holdings, Inc.
RVPH
·
Other OTC
Compare
-
MAIA Biotechnology, Inc.
MAIA
·
New York Stock Exchange Arca
Compare